Using FLT3 Inhibitors to Treat Acute Myeloid Leukemia
A team of researchers at Mass General Cancer Center has reviewed the state of research surrounding FLT3 inhibitors.
About Amir Fathi, MD
Clinical Interests:
- Acute Lymphocytic Leukemia
- Acute Myelogenous Leukemia
- Chronic myelogenous leukemia
- Myelodysplastic syndrome (MDS)
- Myeloproliferative diseases
Treats:
- Adult
Locations
Mass General Cancer Center: Hematology Oncology
55 Fruit St.
Boston, MA 02114
Phone: 617-726-5130
Phone: 877-726-5130
Medical Education
- MD, Yale University School of Medicine
- Fellowship, Johns Hopkins Hospital***
American Board Certifications
- Hematology, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
- Medical Oncology, American Board of Internal Medicine
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Cigna
- Commonwealth Care Alliance
- Coventry
- Fallon Health
- Harvard Pilgrim Health Care
- Humana
- Maine Community Health Options
- Mass General Brigham Health Plan
- MassHealth
- Medicaid CT
- Medicaid ME
- Medicaid NH
- Medicaid RI
- Medicaid VT
- Medicare
- Medicare ACO
- Multiplan
- Railroad Medicare
- Senior Whole Health
- TriCare
- Tufts Health Plan
- United Health Care
- Wellpoint
- WellSense
- WellSense NH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
My research is focused on the development and clinical translation of novel therapies for acute leukemias. I currently lead multiple clinical trials at the Dana Farber Harvard Cancer Center for patients with advanced leukemia and hematologic malignancies. I have a specific interest in studying FLT3 inhibition, aurora kinase inhibition, and antibody-drug conjugates as novel therapies.
Publications
-
Select Publications:
Fathi AT, DiNardo CD, Kline I, Kenvin L, Gupta I, Attar EC, Stein EM, De Botton S. Differentiation syndrome associated with enasidenib (AG-221), a selective inhibitor of mutant isocitrate dehydrogenase 2. JAMA Oncol, 2018;4(8):1106-10.
Fathi AT, Erba HP, Lancet JE, Stein EM, Ravandi F, Faderl S, Walter RB, Advani AS, DeAngelo DJ, Kovacsovics TJ, Jillella AP, Bixby D, Levy MY, O'Meara MM, Ho PA, Voellinger J, Stein AS. A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood, 2018;132(11):1125-33.
Brunner AM, Neuberg D, Wander SA, Sadrzadeh H, Ballen K, Amrein P, Attar E, Hobbs G, Chen YB, Perry A, Joseph C, Burke M, Ramos A, Galinsky I, Yen K, Yang H, Straley K, Agresta S, Adamia S, Borger, DR, Iafrate, A, Graubert TA, Stone R, Fathi AT. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer, 2019;125(4):541-9.
Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, Sekeres MA, Stein A, Kantarjian HM, Levine RL, Vyas P, MacBeth KJ, Tosolini A, Van Oostendorp J, Xu Q, Gupta I, Lila T, Risueno A, Yen KE, Wu B, Attar EC, Tallman MS, de Botton S. Molecular clearance and response patterns in patients treated with enasidenib, an oral inhibitor of mutant IDH2 proteins. Blood, 2019;133(7):676-87.